Absci (ABSI) Projected to Announce Earnings on Tuesday

Absci (NASDAQ:ABSI) is projected to release its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect Absci to announce earnings of ($0.15) per share and revenue of $0.8860 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Absci (NASDAQ:ABSI) last posted its earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. Absci had a negative net margin of 6,450.76% and a negative return on equity of 66.32%. The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $1.39 million. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Stock Performance

Shares of ABSI traded up $0.56 during trading hours on Tuesday, hitting $8.48. The stock had a trading volume of 768,227 shares, compared to its average volume of 4,605,672. The firm has a 50-day moving average price of $8.35 and a 200 day moving average price of $5.14. Absci has a fifty-two week low of $2.24 and a fifty-two week high of $12.06. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -10.25 and a beta of 2.35.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a report on Friday, July 17th. Leerink Partners began coverage on shares of Absci in a research note on Thursday, June 4th. They set an “outperform” rating and a $12.00 target price on the stock. Morgan Stanley restated a “positive” rating and set a $10.00 target price on shares of Absci in a research report on Thursday, June 25th. HC Wainwright lifted their price target on Absci from $8.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target (up from $7.00) on shares of Absci in a report on Wednesday, June 24th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $13.43.

Institutional Investors Weigh In On Absci

A number of hedge funds have recently modified their holdings of the company. Commonwealth Equity Services LLC purchased a new position in shares of Absci during the 4th quarter worth $50,000. Xponance LLC purchased a new stake in shares of Absci during the fourth quarter worth $37,000. CIBC Bancorp USA Inc. purchased a new position in Absci in the third quarter valued at $43,000. Jain Global LLC purchased a new stake in Absci during the 3rd quarter worth about $104,000. Finally, Brooklyn Investment Group increased its holdings in Absci by 13,498.1% during the 3rd quarter. Brooklyn Investment Group now owns 21,485 shares of the company’s stock worth $65,000 after purchasing an additional 21,327 shares during the period. Hedge funds and other institutional investors own 52.05% of the company’s stock.

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.